Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you think this helps or hurts zap . http://www.nbcnewyork.com/news/local-beat/Driving-a-New-Electric-Car--in-NYC-No-Less-104310074.html
http://pr-usa.net/index.php?option=com_content&task=view&id=502301&Itemid=29
GeoVax Presents at AIDS Vaccine 2010 Conference in Atlanta
Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, presented the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference held in Atlanta from September 28 to October 1. The talk, given on Thursday, September 30 in a symposium titled "Blocking HIV/SIV Transmission," reported the findings of a preclinical study conducted at the Yerkes National Primate Research Center at Emory University led by Drs. Lilin Lai, Rama Amara and Robinson. The study was supported by GeoVax with funding provided through an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
The team used simian immunodeficiency virus (SIVmac)239 vaccines and a heterologous SIVsmE660 challenge in rhesus macaques to test the utility of co-expressed GM-CSF in the DNA vaccine. The inclusion of the GM-CSF in the vaccine increased protection from 25% to 71%. The protection appeared to completely block infection (versus merely controlling infection), providing what is called "sterilizing" immunity, a highly desirable characteristic for an AIDS vaccine. Impressively, the protection was against 12 weekly intrarectal exposures at a dose estimated to be 100 to 1,000 times higher than typical human exposures during heterosexual transmission.
Dr. Robinson said, "Our results suggest that a GM-CSF-adjuvanted DNA/MVA HIV/AIDS vaccine may be able to achieve much higher levels of prevention of infection than achieved in the ground-breaking study in Thailand in which 31% of participants were protected by a vaccine."
A correlate, or marker, for the immune responses that had blocked infection, was the avidity (tightness of binding) of the vaccine-induced antibodies for the envelope glycoprotein of the challenge virus. The HIV-1 envelope glycoprotein is the "key" for HIV-1 entry into cells. "This is the first time prevention of infection has been associated with a vaccine-induced antibody response and is an exciting result for the AIDS vaccine field where a primary goal has been to raise antibody that can block incoming virus," said Dr. Robinson.
The adjuvanted vaccine study establishes a new benchmark for protection in the preclinical SIV model, achieving a level of protection that is similar to the highly successful polio vaccine. The unadjuvanted HIV-1 form of the vaccine has proven to be both safe and immunogenic in human clinical trials and has advanced to a Phase 2a trial through the US NIH sponsored HIV Vaccine Trials Network. "Historically, the use of GM-CSF in humans has been quite safe," said Dr. Robinson. "Thus there is considerable promise for successful translation of these preclinical findings into human protection."
"We continue to move forward with the current version of our vaccine in Phase 2 human trials and have no plans to alter that program," said Dr. Robert McNally, CEO of GeoVax. "But the data from this study are so compelling that we are accelerating the planning to move the GM-CSF-adjuvanted vaccine into human trials as quickly as possible. Should the current version of our vaccine prove suboptimal, the adjuvanted vaccine will be a strong reserve – and at the very least, it could become the second generation of our HIV vaccine."
About AIDS Vaccine 2010
Since the first conference, organized in Paris in 2000, the AIDS Vaccine conference has become one of the most important annual events for the exchange of scientific information relating to HIV vaccine research and development. Beginning in 2007, the annual conference is organized under the aegis of the Global HIV Vaccine Enterprise and contributes to the goals of the Enterprise by providing a venue for an international exchange of information in HIV vaccine research and development, cross-fertilizing scientific areas of research, increasing coordination and communication among international groups, and monitoring progress in the field. For more information, please visit http://www.hivvaccineenterprise.org/conference/2010.
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Earlier this year, patient enrollment began in a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's
http://pr-usa.net/index.php?option=com_content&task=view&id=502301&Itemid=29
GeoVax Presents at AIDS Vaccine 2010 Conference in Atlanta
Date : 10/01/2010 @ 7:30AM
Source : PR Newswire
Stock : GeoVax Labs, Inc. Common Stock (GOVX)
Quote : 1.93 0.0 (0.00%) @ 8:04AM
http://ih.advfn.com/p.php?pid=nmona&article=44615613&symbol=NB%5EGOVX
GeoVax Presents at AIDS Vaccine 2010 Conference in Atlanta
GeoVax Labs, Inc. Common Stock (OTCBB:GOVX)
Intraday Stock Chart
Today : Friday 1 October 2010
Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, presented the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference held in Atlanta from September 28 to October 1. The talk, given on Thursday, September 30 in a symposium titled "Blocking HIV/SIV Transmission," reported the findings of a preclinical study conducted at the Yerkes National Primate Research Center at Emory University led by Drs. Lilin Lai, Rama Amara and Robinson. The study was supported by GeoVax with funding provided through an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
The team used simian immunodeficiency virus (SIVmac)239 vaccines and a heterologous SIVsmE660 challenge in rhesus macaques to test the utility of co-expressed GM-CSF in the DNA vaccine. The inclusion of the GM-CSF in the vaccine increased protection from 25% to 71%. The protection appeared to completely block infection (versus merely controlling infection), providing what is called "sterilizing" immunity, a highly desirable characteristic for an AIDS vaccine. Impressively, the protection was against 12 weekly intrarectal exposures at a dose estimated to be 100 to 1,000 times higher than typical human exposures during heterosexual transmission.
Dr. Robinson said, "Our results suggest that a GM-CSF-adjuvanted DNA/MVA HIV/AIDS vaccine may be able to achieve much higher levels of prevention of infection than achieved in the ground-breaking study in Thailand in which 31% of participants were protected by a vaccine."
A correlate, or marker, for the immune responses that had blocked infection, was the avidity (tightness of binding) of the vaccine-induced antibodies for the envelope glycoprotein of the challenge virus. The HIV-1 envelope glycoprotein is the "key" for HIV-1 entry into cells. "This is the first time prevention of infection has been associated with a vaccine-induced antibody response and is an exciting result for the AIDS vaccine field where a primary goal has been to raise antibody that can block incoming virus," said Dr. Robinson.
The adjuvanted vaccine study establishes a new benchmark for protection in the preclinical SIV model, achieving a level of protection that is similar to the highly successful polio vaccine. The unadjuvanted HIV-1 form of the vaccine has proven to be both safe and immunogenic in human clinical trials and has advanced to a Phase 2a trial through the US NIH sponsored HIV Vaccine Trials Network. "Historically, the use of GM-CSF in humans has been quite safe," said Dr. Robinson. "Thus there is considerable promise for successful translation of these preclinical findings into human protection."
"We continue to move forward with the current version of our vaccine in Phase 2 human trials and have no plans to alter that program," said Dr. Robert McNally, CEO of GeoVax. "But the data from this study are so compelling that we are accelerating the planning to move the GM-CSF-adjuvanted vaccine into human trials as quickly as possible. Should the current version of our vaccine prove suboptimal, the adjuvanted vaccine will be a strong reserve – and at the very least, it could become the second generation of our HIV vaccine."
About AIDS Vaccine 2010
Since the first conference, organized in Paris in 2000, the AIDS Vaccine conference has become one of the most important annual events for the exchange of scientific information relating to HIV vaccine research and development. Beginning in 2007, the annual conference is organized under the aegis of the Global HIV Vaccine Enterprise and contributes to the goals of the Enterprise by providing a venue for an international exchange of information in HIV vaccine research and development, cross-fertilizing scientific areas of research, increasing coordination and communication among international groups, and monitoring progress in the field. For more information, please visit http://www.hivvaccineenterprise.org/conference/2010.
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Earlier this year, patient enrollment began in a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
Contact:
At The Investor Relations Group:
Investor Relations
James Carbonara
or
Public Relations
Janet Vasquez / Robin O'Malley
(212) 825-3210
This is a deal that Charles put together with ssta .. you can see that we were going to profit as shareholders .. And when ssta did not come through with the deal as printed . Instead of taking the money and running. Charles halted the transaction and saved are shares, If you research this you will find that ssta, tried to get a 1 in 100 reverse split out of the shareholders. It was a very intersting time to say the least. My point being and why i believe this is relative, is that Charles had an chance to cash in and run,but did not.
Here is the release to shareholders maybe it will set your mind at ease ..Just a little
To the Shareholders of MOP Environmental
On November 26, 2008, we completed an asset purchase transaction with Silver Star Capital Holdings Inc. This transaction included the transfer of certain rights and obligations under an Intellectual Property License and Option Agreement
for the manufacture and sale of MOP Maximum Oil Pickup. Included in the transaction we sold machinery and equipment used to produce MOP and, in consideration of these assets, our shareholders will receive one share of Silver Star Capital Holdings common stock (OTC: SSTA) for every seven shares of MOP Environmental Solutions common stock owned as at the transaction date (October 16, 2008).
The shares of common stock which you will be receiving are the result of an issuance made as payment for the assets purchased by Silver Star Capital Holdings, not an exchange. You retain your respective ownership interests in the company as shareholders of MOP Environmental Solutions.
Going forward, we plan to focus on the production and sale of energy
derived from the oil recovered from used MOP products (“Oil Saturated MOP”). In this pursuit we will be working directly with ECO-Science & Technology Inc., a wholly owned subsidiary of Silver Star Capital Holdings engaged in the manufacture, distribution and sale of MOP products and equipment. We estimate that energy produced from Oil Saturated MOP will generate revenues in excess of $1 million within the next 12 months of operations.
In addition, management plans to acquire Bath Electric Power Company (BEPCO), an independent hydro-electric power plant located in Bath, New Hampshire in a transaction valued at approximately $3.2 million.
The transaction with Silver Star Capital Holdings and the acquisition of BEPCO is consistent with a newly adopted business strategy which seeks restructure the company as a producer of GREEN electric energy and alternative GREEN fuels derived from waste materials otherwise destined for landfills.
We are excited about our opportunities as an energy company utilizing innovative and thoroughly proven technology. Our business proposition presents a wide range of benefits surpassing any presently known alternative for producing low cost GREEN fuel and energy, and will create significant value for all of our stakeholders.
For additional information or questions, please feel free to contact me by email at: mop@mopenvironmental.com
Yours faithfully,
Charles Diamond
President
I don't understand your point. Paid advertising is part of doing business .. what has MOPN done wrong.
Don't you think this quote from oil is a little extreme without validation.
" mop then the share holders would be left with the absorbent towels to wipe their tears as Charlie thinks up his next scheme and runs off into the sunset with the majority of the share holders money in his pocket free and clear."
I'm sure we all want that . But at some point we have too be positive about the small victories. Not to say that i agree with all they do . But i do believe they do enough right things to make this company move in a forward direction . of course IMO
Do you realize how few companies are making a profit in today's economy. And your say if it is confirmed that MOPN is making a profit, that you will just have to be okay with that . Are you kidding me.
thank you !
Jonway Celebrates ZAP Acquisition at Taizhou Factory
Zap (BB) (OTCBB:ZAAP)
Intraday Stock Chart
Today : Monday 27 September 2010
Zhejiang Jonway Automobile Co. Ltd. of Taizhou, China announced its acquisition agreement with U.S. electric vehicle pioneer ZAP (OTCBB:ZAAP) to the Chinese media Friday, which included a ceremony and celebration attended by thousands at its factory for the A380 SUV.
ZAP CEO Steve Schneider with Jonway Auto officials celebrate new auto and electric vehicle venture in China. (Photo: Business Wire)
ZAP's acquisition of Jonway Auto is the most significant business transaction of its kind this year in Taizhou, a coastal city of six million people, said ZAP CEO Steve Schneider and Jonway Auto CEO Alex Wang. The two hosted an event Friday with thousands in attendance, including autoworkers, politicians, business leaders and media.
The celebration for the new venture between ZAP and Jonway Auto continued over the weekend. ZAP Jonway sponsored Taizhou's Green Crab Festival on Saturday, an annual event that attracted more than 18,000 people, including several Hong Kong movie stars and celebrities. The Green Crab festivities aired on major television networks throughout China, highlighting the "green" connection to ZAP Jonway.
The celebration and ceremonies accompany a series of business meetings to advance the goals of the newly formed company, ZAP Jonway, which combines ZAP electric vehicle expertise with Jonway's manufacturing capabilities. Business proceedings continue this week and company officials expect further announcements over the next several days.
About ZAP
ZAP is one of the oldest and most experienced EV providers, having delivered over 117,000 of a broad range of vehicles to more than 75 countries since 1994. ZAP supplies electric trucks and vans to military, government and corporate fleets and is an innovator of electric motorcycles, scooters and ATVs. The Santa Rosa, California based company offers some of the only electric city-speed cars and trucks in production today. ZAP is also developing a freeway capable electric vehicle called the Alias. Further news and information is available at http://zapglobal.wordpress.com.
Safe Harbor Statement
This press release contains forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of ZAP's products, increased levels of competition, new products and technological changes, ZAP's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the ZAP's periodic reports filed with the Securities and Exchange Commission.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6443931&lang=en
GeoVax to Present at Aids Vaccine 2010 Conference in Atlanta
Date : 09/27/2010 @ 7:30AM
Source : PR Newswire
Stock : GeoVax Labs, Inc. Common Stock (GOVX)
Quote : 2.15 0.0 (0.00%) @ 7:25AM
http://ih.advfn.com/p.php?pid=nmona&article=44537675&symbol=NB%5EGOVX
GeoVax to Present at Aids Vaccine 2010 Conference in Atlanta
GeoVax Labs, Inc. Common Stock (OTCBB:GOVX)
Intraday Stock Chart
Today : Monday 27 September 2010
Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, will present the results of a study using granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant for the GeoVax DNA/MVA vaccine at the AIDS Vaccine 2010 conference to be held in Atlanta from September 28 to October 1. The talk, to be given on Thursday, September 30th in a symposium titled "Blocking HIV/SIV Transmission" will report the findings of a preclinical study conducted at the Yerkes National Primate Research Center at Emory University led by Drs. Lilin Lai, Rama Amara and Robinson. The study was supported by GeoVax with funding provided through an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).
The team used simian immunodeficiency virus (SIVmac)239 vaccines and a heterologous SIVsmE660 challenge in rhesus macaques to test the utility of co-expressed GM-CSF in the DNA vaccine. The inclusion of the GM-CSF in the vaccine increased protection from 25% to 71%. The protection appeared to completely block infection (versus merely controlling infection), providing what is called "sterilizing" immunity, a highly desirable characteristic for an AIDS vaccine. Impressively, the protection was against 12 weekly intrarectal exposures at a dose estimated to be 100 to 1000 times higher than typical human exposures during heterosexual transmission.
Dr. Robinson said, "Our results suggest that a GM-CSF-adjuvanted DNA/MVA HIV/AIDS vaccine may be able to achieve much higher levels of prevention of infection than achieved in the ground-breaking study in Thailand in which 31% of participants were protected by a vaccine."
A correlate, or marker, for the immune responses that had blocked infection, was the avidity (tightness of binding) of the vaccine-induced antibodies for the envelope glycoprotein of the challenge virus. The HIV-1 envelope glycoprotein is the "key" for HIV-1 entry into cells. "This is the first time prevention of infection has been associated with a vaccine-induced antibody response and is an exciting result for the AIDS vaccine field where a primary goal has been to raise antibody that can block incoming virus," said Dr. Robinson.
The adjuvanted vaccine study establishes a new benchmark for protection in the preclinical SIV model, achieving a level of protection that is similar to the highly successful polio vaccine. The unadjuvanted HIV-1 form of the vaccine has proven to be both safe and immunogenic in human clinical trials and has advanced to a Phase 2a trial through the US NIH sponsored HIV Vaccine Trials Network. "Historically, the use of GM-CSF in humans has been quite safe," said Dr. Robinson. "Thus there is considerable promise for successful translation of these preclinical findings into human protection."
"We continue to move forward with the current version of our vaccine in Phase 2 human trials and have no plans to alter that program," said Dr. Robert McNally, CEO of GeoVax. "But the data from this study are so compelling that we are accelerating the planning to move the GM-CSF-adjuvanted vaccine into human trials as quickly as possible. Should the current version of our vaccine prove suboptimal, the adjuvanted vaccine will be a strong reserve – and at the very least, it could become the second generation of our HIV vaccine."
About AIDS Vaccine 2010
Since the first conference, organized in Paris in 2000, the AIDS Vaccine conference has become one of the most important annual events for the exchange of scientific information relating to HIV vaccine research and development. Beginning in 2007, the annual conference is organized under the aegis of the Global HIV Vaccine Enterprise and contributes to the goals of the Enterprise by providing a venue for an international exchange of information in HIV vaccine research and development, cross-fertilizing scientific areas of research, increasing coordination and communication among international groups, and monitoring progress in the field. For more information, please visit http://www.hivvaccineenterprise.org/conference/2010.
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, oversee manufacturing and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Earlier this year, patient enrollment began in a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit http://www.geovax.com.
Forward-Looking Statements
Certain statements in this document
Guys this is not Wall street .
Charlie owns the company and has controlling interest of shares .
You on the other hand like the rest of us, are a pinkie , investor .
You have the right to make monies how you can ,when you can, with the shares the you decide to own.
That is it , get over it.
Israel has sizeable deposits of oil shale, perhaps 600 million tons recoverable, with average production of about 9,000 bbl/d. Most of Israel's shale oil resources are located in the Rotem basin region of the northern Negev desert near the Dead Sea. Oil shale is sedimentary rock containing organic material from which liquid fuel may be extracted, at a rate of perhaps 15-17 gallons of oil per ton of shale. Maybe this is where they had the miss information from
http://palestinewater.com/s/israelpower_old/
China looks set to be hugely competitive and now a new name has been added to the list of competing manufacturers.
ZAP and Jonway Group have signed definitive agreements that will see ZAP acquire a 51 per cent stake of Zhejiang Jonway Automobile Company in part of a strategy to capitalise on the growing automotive and electric vehicle market in China.
ZAP Jonway plans to introduce an electric A280.
As part of the agreement, ZAP will acquire 51 per cent of Jonway Auto for US$29.03million. It’s easy to see why ZAP has made a move for the company as it reported annual revenues of around US$40million in 2009 and around US$20million the first quarter of 2010 alone.
ZAP also has the rights to acquire the remaining 49 per cent of Jonway Auto at the same valuation by March 30, 2011, or at a then current valuation after that date. It is intended that this will be phase one of a two phase acquisition with the two companies to combine their expertise leveraging ZAP’s electric vehicle technology and Jonway Auto’s mass production capabilities.
It is believed that the merger will accelerate the cost effective manufacturing of ZAP electric vehicles while also giving ZAP access to the Chinese market. Steve Schneider, the CEO of ZAP Jonway, commented that the new company would create an integrated worldwide sales and manufacturing operation.
At the moment, Jonway Automobile manufactures around 1,000 vehicles per month and has approximately 800 employees. It has a capacity to produce up to 30,000 vehicles a year at its 3.6million sq ft plant in Sanmen.
http://www.thegreencarwebsite.co.uk/blog/index.php/2010/09/21/zap-aims-to-move-in-on-chinese-electric-vehicle-market/
ZAP officially takes over Jonway UFO, to start selling electric cab next year
20 September 2010
At the Chengdu Auto Forum, ZAP CEO Mr. Steve Schneider announced that ZAP have officially taken over Zhejiang’s Jonway UFO brand in a bid to further the electric car market.
A more official announcement regarding the buyout of Jonway UFO is expected to be made later next week at a news conferences. In a later interview with auto.sohu.com, Mr. Schneider revealed that they are not aiming for China to become the largest market for ZAP’s electric vehicles, but they hope that it will remain an important one. ZAP are aiming to start selling an electric version of the UFO SUV to taxi fleets in China, which account for a large percentage of sales. Later in the interview, Mr. Schneider goes into the problem of pushing electric vehicles into the mass market rather than leaving them in the sidelines as niche vehicles, which has so far been the problem for electric car manufacturers.
http://www.chinacartimes.com/2010/09/20/zap-officially-takes-over-jonway-ufo-to-start-selling-electric-cab-next-year/
Yes,Sorry about that,pretty small blip for such a large article.
Tried high lighting zap but couldn't. But thank you for the follow up article.
read the full article ...states that they came out and paid a visit to zap.Also shows that other countries are looking for a new source of power
Exclusive: Iceland entrepreneurs on fast track for electric car revolution
Our blogger traveled to Iceland to find out how one company is bucking a deep recession to build the world's first all-electric transportation network.
Fri, Sep 17 2010 at 11:54 AM EST
MAN ON A MISSION: Gisli Gislason with the first Tesla in Europe. (Photo: Jim Motavalli)
REYKJAVIK, ICELAND -- Yes, Iceland is financially depressed, and the car market has plummeted an amazing 80 to 90 percent since the country’s banking crisis hit. But that hasn’t stopped a small but ambitious band of green-minded entrepreneurs, gathered at this week’s Driving Sustainability 2010 conference in Reykjavik, from planning a makeover for the country’s transportation fleet.
With an environmentally friendly population of just 300,000 souls clustered around the capital city, plus abundant geothermal and hydro electricity potential (10 times what the country could actually use), Iceland is uniquely positioned to plug in. And a new company called Even, a spinoff of Northern Lights Energy, thinks it can lead the charge, having already signed up 50 leading companies to buy fleets of electric vehicles and charge them from Even-supplied fast-charging stations.
According to Even founder Gisli Gislason, major banks, the national postal service, a leading phone company, and five municipalities have signed onto the plan, which will launch formally in a few months when it has 100 signatories. Gislason is also signing up cars for resale in Iceland, and has a standing order for 1,000 Tesla Model S models, which hit the road in 2012. Gislason bought the first Tesla Roadster delivered in Europe, and it was on display at the conference.
Even also has orders for 100 cars made by India’s Reva (maker of the G-Wiz) and (probably the first to arrive) 20 trucks from the Britain-based Smith Electric Vehicles (which just announced a major sale to PepsiCo’s Frito-Lay division). Many electric vehicle makers have had visits from Gislason, including Zap and the Norway-based Think (which is to get its first small fleet of City vehicles next month as part of a car-sharing operation Even is involved in).
The Even plan uses a subscription model. According to Even’s Sturla Sighvatsson, consumers in Iceland will pay just $35 a month for unlimited home or public charging, which is intended to be high-voltage AC “fast charging,” which can take a car from zero to full in just half an hour.
Iceland’s original plan was to transform the country’s transportation fleet with hydrogen, and to that end it opened a hydrogen station and imported three Mercedes Citaro fuel-cell buses. But the buses ran for only three years, and it proved difficult for Iceland (no auto company’s idea of a major market) to lure fuel-cell vehicles. Hydrogen could be a long-term prospect, however, since it’s one way to store excess electricity capacity.
Several years ago, the Icelandic government signed a memorandum of understanding with Mitsubishi (already a supplier to the country’s geothermal industry) to supply i-MiEV electric cars. The Icelanders envisioned a fleet of several hundred, but so far only two or three cars have been delivered. It probably doesn’t help that the local Mitsubishi dealer was taken over by the banks (as have many other local car dealers unable to survive the crash).
Even’s plan won’t work unless there are actual electric vehicles to plug in to the new chargers. I personally think a great solution would be to convert cars to electric right here in Iceland, but despite the existence of plants making ambulances, fire engines and the monster trucks that make a sport of outback driving, there’s no EV conversion yet.
http://www.mnn.com/transportation/cars/blogs/exclusive-iceland-entrepreneurs-on-fast-track-for-electric-car-revolution
Thank you SUNB.. great answer !
That will be great to see.
MOP Environmental Solutions, Inc. expected to report Q3 2010 results on October 27, 2010. This event was calculated by Capital IQ (Created on August 12, 2010).
http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=MOPN:US
Yes , really thought they had a chance. But I do still believe we are ahead of the pack for production cars.
I hope as shareholders ,that want mop to do well .. so that we also can profit. That we have all learned a very valuable lesson.
Excellent job on that.
China Government Approves ZAP Acquisition of Majority Stake in Jonway Auto
http://www.marketwatch.com/story/china-government-approves-zap-acquisition-of-majority-stake-in-jonway-auto-2010-09-16?reflink=MW_news_stmp
SANTA ROSA, Calif. & ZHEJIANG, China, Sep 16, 2010 (BUSINESS WIRE) -- The Commerce Department of Zhejiang Province in China has approved ZAP's /quotes/comstock/11k!zaap (ZAAP 0.49, +0.01, +2.08%) proposed acquisition of a 51 percent equity interest in Zhejiang Jonway Automobile Co. Limited. ZAP and Jonway now intend to move forward to satisfy the remaining conditions to closing the transaction, including but not limited to those related to financing, foreign exchange authority approval in China and share registration.
According to the terms of the definitive agreements, ZAP has the right to acquire the remaining 49% of Zhejiang Jonway Automobile Co. Limited at the same valuation by March 30, 2011 or at a then current valuation after that date.
ZAP intends to capitalize on the growing automotive and electric vehicle (EV) market in China through the proposed acquisition of a majority stake in Zhejiang Jonway Automobile Co. Limited. ZAP is a 16-year-old company located in California with expertise in EV design, while Zhejiang Jonway Automobile Co. Limited is a manufacturing subsidiary of Jonway Group, a 20-year-old vehicle manufacturer in China.
Safe Harbor Statement
This press release contains forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of ZAP's products, increased levels of competition, new products and technological changes, ZAP's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the ZAP's periodic reports filed with the Securities and Exchange Commission.
SOURCE: ZAP
ZAP Jonway USA
Alex Campbell, +1-707-525-8658 ext. 241
acampbell@zapworld.com
or
ZAP Jonway China
Jessica Gao, +86 13511038395
juan.gao@zapworld.com
Copyright Business Wire 2010
Most Popular
Most readMost commented
Stock futures fall as FedEx disappoints
Weekly jobless claims fall 3,000 to 450,000
U.S. stocks slip after mixed economic data
Ford shares jump 5% on analyst upgrade
Geithner calls for faster yuan appreciation
Is tea party end of our two-party system?
Weekly jobless claims fall 3,000 to 450,000
U.S. stocks end higher after Japan’s intervention
Ineffective TARP limits future options, panel says
Don’t judge a 'book' by its cover
Find a Broker Partner Center »
MarketWatch's Latest Tweets
"U.S. retirement income deficit: $6.6 trillion http://bit.ly/d3903o"
12:16 p.m. EDT, Sept. 16, 2010 from MarketWatch
"#Oracle seen posting big gain in profit http://bit.ly/aHxPE2"
11:47 a.m. EDT, Sept. 16, 2010 from MarketWatch
"Geithner calls for faster yuan appreciation http://bit.ly/cX7Duw"
11:20 a.m. EDT, Sept. 16, 2010 from MarketWatch
"Jobless claims drop 3,000 to 450,000 http://bit.ly/daWrE8"
10:37 a.m. EDT, Sept. 16, 2010 from MarketWatch
"Room to talk on #tax cuts, Hoyer says http://bit.ly/cEdYxC"
4:39 p.m. EDT, Sept. 15, 2010 from MarketWatch
Lets hope it creates some interest!
No .. I'm blaming it on us as shareholders ... the flippers are doing great, They have a single minded purpose and they stick to it .. we change are mind when the wind blows and then put it out there for them to feed on...
Hey I have been in this stock for over 5 years, I don't care what the price is this afternoon either. Just don't understand why the same people that will cut on mop one minute and the next they are complaining about the price off the stock
Just a side note.. do you realize the hard work that probably went into this deal. And we let the flippers turn good news into a piece of crap..NICE
Okay .. and then by this afternoon everyone will be complaining about the price of the stock .. And what is Charles going to do about it.
Yes. So why not give mop the same respect.. If Bib says mop is okay to use there money .. come on guys. For every step forward Charles takes .. you push him back three.
Exactly he is a customer that is going to buy mop products .. good point 7. Hey but keep letting them drive the price down . I'll take another 100,000 shares at a penny
:) man was that good .. all the way to the bank
Thank you for the info.
ZAP Jonway Alias Electric Car on Display in Washington DC Today
100+ MPGe Electric Car in Progressive Insurance Automotive X PRIZE Awards Ceremony Followed by Presentation to U.S. Department of Energy Secretary Steven Chu
WASHINGTON, Sept 16, 2010 /PRNewswire via COMTEX/ -- The Alias electric car from ZAP Jonway /quotes/comstock/11k!zaap (ZAAP 0.48, 0.00, 0.00%) will be participating in two events in Washington, D.C. on Thursday, September 16, 2010. From 10:30 AM - 12:00 PM, the Alias will be featured as a finalist in the Progressive Insurance Automotive X PRIZE Awards Ceremony at the Historical Society of Washington, D.C. From 2:15 to 2:45 PM the Alias will be presented to U.S. Department of Energy Secretary Steven Chu.
EVENT 1 PROGRESSIVE INSURANCE AUTOMOTIVE X PRIZE
CELEBRATION & AWARDS CEREMONY
10:30 AM - 12:00 PM, Thursday, September
WHEN: 16, 2010
ZAP Jonway Alias Team Members as well as
officials and other teams competing in the
WHO: Progressive Insurance Automotive X PRIZE
WHERE: Historical Society of Washington, D.C.
801 K Street NW at Mount Vernon Square,
Washington, DC
Alias is one of nine finalists for the $10
Million Progressive Insurance Automotive X
WHY: PRIZE for 100 MPGe cars
EVENT 2 U.S. DEPARTMENT OF ENERGY PRESENTATION
2:15-2:45 PM (), Thursday, September
WHEN: 16, 2010
Photo and Interview Opportunity with U.S.
WHO: DOE Secretary Steven Chu
ZAP Jonway Alias Team Members, X PRIZE
Officials
WHERE: U.S. Department of Energy
1000 Independence Ave. SW, Washington, D.C.
SOURCE ZAP Jonway
Copyright (C) 2010 PR Newswire. All rights reserved
You absolutely have that right !
Daddy come on .There are alot of business people that don't have a great reputation. And I know for most pinkie trades people need all the smoke and mirrors. But mopn is a real company . As long as future volume of product goes up, this will mean nothing